Rising TMC development names Houston health care institution as anchor tenant

coming soon

The Dynamic One building in TMC Helix Park is expected to deliver later this year. Rendering via TMC.edu

TMC Helix Park, formerly known as TMC3, has announced its first anchor tenant.

The Texas Medical Center and Beacon Capital Partners announced that Baylor College of Medicine will be the anchor tenant of the Dynamic One building at TMC Helix Park. The facility is will be the first to deliver of the four TMC Helix Park industry buildings. The Topped off in December, the Dynamic One building is being developed by Beacon in collaboration with Zoë Life Science and is scheduled to open before the end of the year.

“Beacon is excited that Dynamic One will be our first entry into the fast-growing Houston Life Science market,” says Fred Seigel, president and CEO of Beacon, in a news release. “This state-of-the-art environment is designed to enable and encourage collaboration and will greatly accelerate the innovative lifesaving discoveries that emerge when industry and academic research work side-by-side.”

Baylor College of Medicine will lease 114,000 square-feet of lab and office space in the 355,000-square-foot building. BCM's goal is to house lab space for novel diagnostics and therapeutics — and provide space to house startups.

The organization is expanding its presence in Houston after decades of residing in the region.

“Baylor College of Medicine moved to Houston in 1943 and was the first institution built in the Texas Medical Center," says Dr. Paul Klotman, president and CEO and executive dean of Baylor, in the release. "Our researchers and scientists will have the opportunity to access the uniquely concentrated research environment being developed at TMC Helix Park, facilitating the continuing advancement of innovation and compassionate care."

TMC Helix Park, which includes more than 5 million-square-feet of space across 37-acres, also expects to deliver its research facility, the TMC3 Collaborative Building, later this year.

“Baylor College of Medicine is a major force in life sciences discovery and commercialization at TMC," says Bill McKeon, president and CEO of TMC, in the release. "Their move to TMC Helix Park will serve as a catalyst for enhanced collaboration with TMC’s other esteemed Institutions, as well as with industry leaders from around the world."

BCM is the first anchor tenant announced for TMC Helix Park. Rendering via TMC.edu

From Your Site Articles
TMC gave an update on TMC3 — now called TMC Helix Park — and introduced a new bioport project. Courtesy of Elkus Manfredi Architects

TMC unveils details of new bioport, Helix Park at annual Greater Houston Partnership event

coming soon

Within the next five to 10 years, the Texas Medical Center you know today will be double the size. That's what Bill McKeon, president and CEO of the TMC, said at yesterday's State of the Texas Medical Center event hosted by the Greater Houston Partnership.

The biggest project contributing to the TMC's growth is TMC3, a campus expansion that will bring 37 acres and 5 million square feet of space to the TMC, is now known as Helix Park. The name is a nod to the shape of the park and walkway design at the center of the campus. The TMC3 Collaborative Building — the first multi-institutional research facility in TMC’s history — will be the first of the project to deliver and is currently under construction and slated for completion in 2023.

However, the big news of the event was the TMC BioPort, the organization's upcoming biomanufacturing and medical supplies distribution engine. This new campus will span several hundred acres just down the road from TMC and will drive the much-needed repatriation of critical medical supplies and new cell and gene therapies, per a news release.

"During COVID, we saw the weakness of our supply chain," McKeon says at the event. "There is a huge effort by this country as a part of national security to make sure drug and vaccine production is moved back into the United States."

The new campus will also have an on-site upskill training center and create over 100,000 new job opportunities.

“Houston is advancing its position as the leading destination for life science discovery,” McKeon says in the release. “Through our holistic, expansive vision, we are building every vital component necessary to advance the largest life science ecosystem in the world.”

As explained at the event, the growing TMC is anchored by four districts: the TMC Medical Campus and the TMC Innovation Factory, which are already fully open and operating for years now, and the upcoming TMC Helix Park and TMC BioPort, which are both underway.


Bill McKeon gave the address at the State of the Texas Medical Center.

TMC3's Collaborative Building has topped out. Image courtesy of Texas Medical Center

First TMC3 Collaborative Building tops out, plans to open next year

medical milestone

Construction of Houston’s 250,000-square-foot TMC3 Collaborative Building has reached a milestone.

Founders of the research facility recently celebrated completion of the uppermost part of the building, known as “topping out.” Construction started in January 2021.

The building is part of the first phase of the TMC3 campus, a 37-acre life science property designed to capitalize on the intersection of medicine and commercialization. Founders of the campus are Texas Medical Center, the University of Texas MD Anderson Cancer Center, Texas A&M University Health Science Center, and the University of Texas Health Science Center at Houston.

The TMC3 Collaborative Building, set to open in 2023, will promote innovation and collaboration among the founding institutions, as well as with academic, healthcare, and industry partners. A key feature is a 43,000-square-foot research lab that’ll be shared by MD Anderson, Texas A&M Health, and UT Health Houston.

“The topping out of the TMC3 Collaborative Building marks an integral milestone in the future of life science research and innovation and reflects an unprecedented commitment to collaboration among the four founding institutions,” William McKeon, president and CEO of Texas Medical Center, says in a news release. “The lifesaving research and technologies that will come out of this building will truly revolutionize healthcare.”

In addition to the research lab, the building will include:

  • 85,000 square feet of lab and office space for industry partners.
  • 14,200 square feet for Texas Medical Center’s strategic initiatives, the Braidwell investment firm, the TMC Venture Fund, and national venture and equity fund partners.
  • A 7,000-square-foot atrium for lectures, programs, and informal events.

“Houston already has a place on the world stage as a leader in clinical care and life sciences. With the launch of the TMC3 Collaborative Building and larger TMC3 campus, we showcase why our city leads in the areas of innovation and technology,” Houston Mayor Sylvester Turner says. “In the process, we will create opportunities to bring new partners and industry to our city and generate new jobs for the residents of the Greater Houston community.”

For the first time, Accenture hosted its HealthTech Innovation Challenge finals at the Texas Medical Center's Innovation Institute. Photo courtesy of Accenture

2 startups win big at Accenture's ​Houston-based health tech competition

winner, winner

Two health tech companies walked away from Accenture's HealthTech Innovation Challenge with awards. Regionals took place in Boston and San Francisco, and Houston was selected to host the finals last week.

New York-based Capital Rx was selected as the 2020 Innovation Champion of the Accenture HealthTech Innovation Challenge, and Minneapolis-based Carrot Health was given the second-place award for Top Innovator. The program, which was first launched in 2016, aims to pair startups with health organizations to drive innovative solutions to real challenges in health care.

"The submissions we received this year demonstrate the momentum of discovery and digital innovation in healthcare," says Brian Kalis, managing director of digital health and innovation at Accenture, in a news release. "Healthcare organizations continue to advance their digital transformation agendas — enhancing access, affordability, quality and experience to drive innovation that improves the lives of consumers and clinicians. We look forward to working with these companies and others to continue to help advance solutions that address the industry's toughest challenges."

Capital Rx, a pharmacy benefit manager, won for its product, the Clearinghouse ModelSM, which connects pharmacies and employers for a more efficient and transparent way to coordinate prescriptions.

"Receiving the designation as Innovation Champion is a validation of our mission to change the way drugs are priced and administered, and it represents the broad support across the country to transform the antiquated and opaque pricing model for prescription drugs," says AJ Loiacono, CEO of Capital Rx, in the release.

Carrot Health, which took second place, has created algorithms to use consumer data analytics to predict and determine health issues. Its MarketView platform weighs in factors including social, economic, behavior, and environmental information.

"It's been a great opportunity to be with Accenture and a broad spectrum of health care players," says Kurt Waltenbaugh, CEO and founder of Carrot Health, in the release. "Being recognized as the Top Innovator will help us expand our footprint toward our goal to change health and serve every person in the U.S."

A total of 11 finalists pitched in Houston at TMCx on Feb, 6. The other finalists included: San Francisco-based Cleo, Boston-based DynamiCare Health, San Francisco-based InsightRX, United Kingdom-based Lantum, Washington, D.C.-based Mira, Denver-based Orderly Health, New York City-based Paloma Health, St. Louis-based TCARE, and Seattle-based Xealth.

It was the first time the challenge was hosted at the Texas Medical Center, and William F. McKeon, TMC president and CEO, took the stage at the event to share the medical city's vision for the future.

"The opportunity to host the HealthTech Innovation Challenge in Houston for the first time re-enforces our city's prominent and ever-expanding designation as a major hub for healthcare innovation nationwide," McKeon says in the release. "As Texas Medical Center heads into a new era of collaborative healthcare research on our forthcoming TMC3 campus, we look forward to maintaining a fruitful long-term partnership with Accenture."

The Texas Medical Center's CEO, Bill McKeon, ran down a list of exciting updates and innovations from the organization's member institutions at the annual State of the TMC. Photo via tmc.edu

From robots to immunotherapy, TMC talks innovation at its annual address

check up

In the Greater Houston Partnership's annual State of the Texas Medical Center address, TMC CEO Bill McKeon shared a status update of sorts for all the goings on at the largest medical center in the world.

McKeon ran down the list of member institutions to briefly touch base on each organization's innovations and growth. In the address, which took place at the Marriott Marquis on October 31, McKeon discussed exciting construction projects, new accelerator programs, and more. Here are some of the highlights from the presentation.

TMC3 and beyond

The TMC spans 1,400 acres and 50 million square feet of development — and growing. The largest medical city in the world will increase its size by 10 percent in the next two to three years, McKeon says. Here are some updates on each of the ongoing construction projects.

  • TMC3 is underway. The 37-acre research campus is expected to be completed in 2022.
  • CHI St. Luke's McNair Campus is expected to break ground on a new building before the end of the year.
  • Memorial Hermann's Sarofim Building is expected to open in 2020 with 18 stories, 26 new operating rooms, and 144 beds
  • Rice University has moved its synthetic biology program to BioScience Research Collaborative in the TMC.
  • Texas A&M University's EnMed program, which graduates students with a master's in engineering and a MD in four year, has launched. The university's med center building is underway at 1020 Holcombe, and is expected to be completed next May.
  • The University of Houston's new medical school us up and running, and the inaugural class's tuition was completely funded by an anonymous donor.
  • UTHealth's psychiatric hospital is expected to be the largest academic psychiatry hospital in country. The building is under construction and will be completed in 2021.

Building biobridges

In order to grow the TMC's global presence and bring the best innovations from around the world to Houston, McKeon says the organization has expanded its BioBridge partnerships.

The first partnership was with Australia in 2016, before the organization teamed up with the United Kingdom for the second one. Recently, the TMC has entered into its third BioBridge partnership with Denmark.

The partnerships are intended to encourage collaboration, particularly with TMCx. Now, TMCx startups break down from being a third of the companies from around the world, a third from other states in the U.S., and a third being from Texas.

"There's no greater collection of minds, patients, resources to really think about the next innovations in health care," Mckeon says.

Accelerating accelerators

TMCx is celebrating its fifth year and has worked with over 170 companies through its digital health and medical device accelerator programs.

"We're evolving to start to work more closely with our member institutions to understand their specific needs and how we can match novel technologies through them," says Lance Black, associate director of TMCx.

The TMC Innovation Institute supports 12 programs, and three have been introduced just this year.

  • TMCxi: A 40,000-square-foot space to support industry partners, investors, and other service providers that provides subject matter expertise and other resources for entrepreneurs.
  • TMCalpha: Programming for TMC doctors and staff who may have an idea for a new technology or startup.
  • TMC | ACT: An accelerator program for advancing cancer therapeutics and technologies.

Investing in robotics

Earlier this year, TMC announced plans to open a special robotics lab space with ABB Robotics. The space officially opened last month.

"Many of the things we do in our labs require pinpoint accuracy," McKeon says. "Many of the things we do now here are done by humans, but in the future, we have one of the most sophisticated robotics companies in the world thinking about how we can transform our labs."

The lab is just the beginning of ABB's connection to TMC and its member institutions.

ABB's mobile YuMi robot cut the ribbon on its new home in the Texas Medical Center. Cody Duty/TMC

Videos: Robotics company unveils its Houston operation at the Texas Medical Center

Meet the robots

Houston has a new fleet of robots training to better streamline health care operations. ABB Robotics cut the ribbon of its Texas Medical Center incubator on Wednesday, October 9.

"This is really an exciting day for us at ABB because we are opening up our innovation hub in a globally unique place at the Texas Medical Center," says Sami Atiya, president of Robotics and Discrete Automation at ABB, at the grand opening event.

According to ABB research, the industry expects 60,000 non-surgical medical robots by 2025, which is four times that of 2018. Zurich-based ABB has 400,000 robotics products across industries in over 53 companies, but this is their first dedicated health care center. The 5,300-square-foot space located in TMC Innovation Institute, which was announced earlier this year, will have around 20 employees in the facility managing robots conducting a myriad of tasks.

The potential for collaboration between ABB and TMC is just getting started with the hub space. ABB already has connections with TMC's member institutions and ABB also recognizes the innovation avenues the TMC brings to the table.

"This is not only about the chance to interact with 25 hospitals," Atiya says. "We have the chance to interact with bright startups, bright academia, and with an ecosystem that is unique. We really looked around the world to set up this business because we need to learn. We need to interact."

One way TMC's CEO, William McKeon sees a huge opportunity for robots is in the inventory process. Right now, each hospital manages its own inventory process with its own team of employees. McKeon explains how that process can be streamlined and better organized using robotics.

"It may not be as exciting as some of the things you see here [in the hub], but it's equally as meaningful and economically important in lowering our health care costs," McKeon says.

YuMi cuts the ribbon on the new ABB facility in the Texas Medical Center

The mobile YuMi robot cut the ribbon of its new home.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice researchers score $45M from NIH for cancer-fighting tech

freshly funded

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

TMC again expands global impact with new Netherlands partnership

breaking news

The Texas Medical Center may be based in Houston, but the organization has again grown its global impact.

Since 2016, TMC’s BioBridges have worked with 88 startup companies. Those include strategic alliances with four other countries. Australia, the United Kingdom, Denmark and Ireland are all among TMC’s BioBridges partners. As of today, add the Netherlands to that list.

On September 27, TMC president and CEO, William F. McKeon, and Carmen van Vilsteren, chair of Health~Holland, Top Sector Life Sciences & Health (LSH), signed an agreement in Rotterdam. The TMC Netherlands BioBridge Memorandum of Understanding codifies the innovative goals of the partnership. Essentially, the BioBridge program provides a means for entrepreneurs, researchers, clinicians and industry partners from other countries to access the US market, as well as TMC experts.

“The TMC Netherlands BioBridge represents an unparalleled opportunity for collaboration and growth,” Ashley McPhail, chief external affairs & administration officer at Texas Medical Center said in a press release. “The Netherlands has solidified its position as a global leader in the field of life sciences and health, with a thriving ecosystem of research institutions, innovative companies, and highly skilled professionals. This strategic partnership will bring positive benefits to patients, clinicians and industry partners on a global scale.”

This lifeline for international healthcare companies makes expansion into the United States far smoother. The Global Innovators Launch Pad allows for startup founders to take part in a 10-week residency at the TMC Innovation Factory that will teach them about foundational infrastructure, clinical evidence and funding in the US.

“Since Texas is an important hub for innovation in the MedTech and digital health sectors, the collaboration with Texas Medical Center creates opportunities for Dutch companies looking to expand their international reach. Vice versa, it gives companies in Texas access to the vibrant Dutch Life Sciences & Health sector,” said van Vilsteren.

That exchange includes members of the TMC gaining the opportunity to participate in the Health~Holland Visitors Programme (HVP), “Shaping the Healthcare of the Future.”

The annual event invites high-level representatives from the private sector, NGOs, knowledge institutions, healthcare providers and different tiers of government to share their expertise.

It's the fifth partnership of its kind for TMC, with the last one being with Ireland, announced last year. TMC's other global initiatives include accelerators with Denmark and the United Kingdom, both announced earlier this year.

Houston startup founders prepare to scale globally following Shark Tank success

HOUSTON INNOVATORS PODCAST EPISODE 205

While Milkify's founders — husband and wife team Pedro Silva and Berkley Luck — secured partners on a popular business pitch and investment show, the entire experience almost didn't happen.

Silva and Luck, who got her PhD in molecular and biomedical s at Baylor College of Medicine, founded the company to provide breast milk freeze drying as a service to Houston-area families. Now, Milkify has customers across the country, but the duo didn't know if going through the process would be worth the investment and publicity, or if it would just be a distraction.

"The competitor in me wanted to be the first breast milk company to go on the show and to tell our story to the world — to show the world what my wife came up with that we thought was so great," Silva says on the Houston Innovators Podcast. "It was probably the scariest 45 minutes of my life."

But the sharks bit. Milkify's episode aired in April, and two investors — Gwyneth Paltrow and Lori Greiner — agreed to a $400,000 convertible note for 20 percent equity in the company. Paltrow even said on the show that she would have used the service when she was breastfeeding.

"It was empowering," Luck says of getting to wear her white coat on TV and share the story of how she came up with the idea of Milkify. "It was important to me when we went on the show to express that this had a scientific basis, that we didn't start this lightly, and that we've made huge strides in doing this in the absolute safest way possible."

Silva says they can't talk about some of the details of the show or the deal, but since then, Milkify has reached new customers, received additional investment interest, grown its team, and built out its plan to scale, the founders shared on the podcast. The team also shares its big-picture scale plans, which include tapping international partners to potentially take Milkify's tech global.

"Our vision is for every family to have access to breast milk formula, but instead of re-creating breast milk in a lab, we're doing it with mom's own milk," Silva says, mentioning a partnership with a breast milk bank that will convert its operation from freezing to freeze drying donated milk. "We're also working with groups in the UK and Australia to launch similar services using our patented technology."

"By the end of the year, we hope to see some announcements with those partnerships across the globe."

From the beginning, the importance of Milkify's team has been on supporting working parents to give them the best way to care for their families, Silva says. And for Luck — who says she's proud of the integrity Milkify has at its core despite competitors offering lower-quality and, in some cases, dangerous alternatives — she sees a lot of research benefits for the company.

"It's amazing to be at this leading edge, not just of innovation but of research, and to be able to still put out meaningful advances as an industry partner, not just as an academic," Luck says, adding that she hopes to be able to continue to contribute to the ongoing research into breast milk.

Luck and Silva share more about their Shark Tank experience, their co-founder strengths, and the future of Milkify on the podcast. Listen to the interview here — or wherever you stream your podcasts — and subscribe for weekly episodes.

View All Listings